Citadel Advisors’s Adverum Biotechnologies ADVM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-24,100
| Closed | -$109K | – | 12533 |
|
|
2025
Q3 | $109K | Buy |
+24,100
| New | +$71K | ﹤0.01% | 11789 |
|
|
2025
Q2 | – | Sell |
-6,100
| Closed | -$26.7K | – | 12343 |
|
|
2025
Q1 | $26.7K | Sell |
6,100
-3,500
| -36% | -$15.8K | ﹤0.01% | 12920 |
|
|
2024
Q4 | $44.8K | Sell |
9,600
-13,600
| -59% | -$91.5K | ﹤0.01% | 12500 |
|
|
2024
Q3 | $163K | Buy |
23,200
+200
| +0.9% | +$1.45K | ﹤0.01% | 10459 |
|
|
2024
Q2 | $158K | Buy |
+23,000
| New | +$214K | ﹤0.01% | 10270 |
|
|
2024
Q1 | – | Sell |
-50
| Closed | -$376 | – | 14473 |
|
|
2023
Q4 | $376 | Sell |
50
-1,520
| -97% | -$13.9K | ﹤0.01% | 14048 |
|
|
2023
Q3 | $23.6K | Buy |
+1,570
| New | +$28.2K | ﹤0.01% | 12489 |
|
|
2023
Q2 | – | Sell |
-2,080
| Closed | -$14.9K | – | 14260 |
|
|
2023
Q1 | $14.9K | Sell |
2,080
-4,610
| -69% | -$32.6K | ﹤0.01% | 13272 |
|
|
2022
Q4 | $38.8K | Buy |
6,690
+3,020
| +82% | +$22.9K | ﹤0.01% | 12453 |
|
|
2022
Q3 | $35K | Sell |
3,670
-1,140
| -24% | -$15K | ﹤0.01% | 11822 |
|
|
2022
Q2 | $58K | Sell |
4,810
-1,800
| -27% | -$18.9K | ﹤0.01% | 11838 |
|
|
2022
Q1 | $87K | Sell |
6,610
-3,420
| -34% | -$50K | ﹤0.01% | 12406 |
|
|
2021
Q4 | $177K | Sell |
10,030
-2,450
| -20% | -$49K | ﹤0.01% | 12033 |
|
|
2021
Q3 | $271K | Buy |
12,480
+6,540
| +110% | +$167K | ﹤0.01% | 11275 |
|
|
2021
Q2 | $208K | Buy |
5,940
+1,590
| +37% | +$85.6K | ﹤0.01% | 12062 |
|
|
2021
Q1 | $429K | Sell |
4,350
-8,810
| -67% | -$1.06M | ﹤0.01% | 10022 |
|
|
2020
Q4 | $1.43M | Buy |
13,160
+6,930
| +111% | +$857K | ﹤0.01% | 6047 |
|
|
2020
Q3 | $642K | Sell |
6,230
-1,170
| -16% | -$175K | ﹤0.01% | 6837 |
|
|
2020
Q2 | $1.54M | Buy |
7,400
+3,310
| +81% | +$586K | ﹤0.01% | 5020 |
|
|
2020
Q1 | $400K | Sell |
4,090
-100
| -2% | -$11.7K | ﹤0.01% | 6834 |
|
|
2019
Q4 | $483K | Sell |
4,190
-10,400
| -71% | -$917K | ﹤0.01% | 6856 |
|
|
2019
Q3 | $795K | Buy |
14,590
+13,340
| +1,067% | +$1.5M | ﹤0.01% | 5983 |
|
|
2019
Q2 | $149K | Buy |
+1,250
| New | +$103K | ﹤0.01% | 8355 |
|
|
2018
Q4 | – | Sell |
-1,230
| Closed | -$74K | – | 9017 |
|
|
2018
Q3 | $74K | Sell |
1,230
-750
| -38% | -$42.1K | ﹤0.01% | 8684 |
|
|
2018
Q2 | $105K | Buy |
+1,980
| New | +$119K | ﹤0.01% | 8217 |
|
|
2015
Q4 | – | Sell |
-560
| Closed | -$46K | – | 8667 |
|
|
2015
Q3 | $46K | Sell |
560
-1,720
| -75% | -$220K | ﹤0.01% | 7639 |
|
|
2015
Q2 | $370K | Buy |
2,280
+2,020
| +777% | +$682K | ﹤0.01% | 5428 |
|
|
2015
Q1 | $105K | Buy |
+260
| New | +$110K | ﹤0.01% | 6808 |
|
Citadel Advisors's ADVM Position: Q4 2025 in Review
Citadel Advisors sold out of Adverum Biotechnologies (ADVM) in Q4 2025, closing a stake of 17,267 shares — an estimated $78.2K sold.
Citadel Advisors first reported a position in ADVM in Q3 2014 and held it in 35 quarters. The position peaked at $18M in Q2 2020. 0 funds tracked by Wall St. Rank hold ADVM as of Q4 2025.
- Citadel Advisors reported no remaining Adverum Biotechnologies position as of Q4 2025 after selling out during the quarter.
- Citadel Advisors sold 17,267 Adverum Biotechnologies shares in Q4 2025, an estimated $78.2K.
- Citadel Advisors first reported a position in Adverum Biotechnologies in Q3 2014 and held it in 35 quarters.
- Citadel Advisors's Adverum Biotechnologies position peaked at $18M in Q2 2020.
- 0 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2025.
Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.